[Limited effect of gonadotrophin-releasing hormone analogues for patients with endometriosis].
A Cochrane review concluded that gonadotrophin-releasing hormone analogues (GnRHas) are more effective at relieving endometriosis-associated pain than no treatment/placebo, while there was not found any difference in pain relief between GnRHas and danazol or between GnRHas and intrauterine levonorgestrel. A high frequency of hypoestrogenic side effects was found for GnRHas, since none of the studies included add-back therapy. This review confirmed that GnRHas can be used for endometriosis therapy, but first choice of medical treatment should be oral contraceptives or intrauterine levonorgestrel.
Gynækologisk Afdeling Y, Aarhus Universitetshospital, Skejby, Brendstrupgårdsvej, 8000 Aarhus C, Denmark. mseyer@dadlnet.dk
Mikkel
M
Seyer-Hansen
Christina
C
Kruse
D003276:Contraceptives, Oral / Q000627:therapeutic use; D003613:Danazol / Q000009:adverse effects / Q000627:therapeutic use; D004715:Endometriosis / Q000188:drug therapy*; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007436:Intrauterine Devices, Medicated; D010147:Pain Measurement; D017699:Pelvic Pain / Q000188:drug therapy; D011372:Progestins / Q000008:administration & dosage / Q000627:therapeutic use
D003276:Contraceptives, Oral; D004965:Estrogen Antagonists; D011372:Progestins; D007987:Gonadotropin-Releasing Hormone; D003613:Danazol